A sequential scanning of the immune efficiency in Astrocytoma (Grade I to Grade III), meningioma and secondary glioma patients with and without therapeutic scheduling

Cancer Investigation

Volumn 24, Issue 5, 2006, Pages 502-513

  Bhattacharjee, M ^a   Bose, I ^a   Sarkar, P ^a   Banerjee, C ^a   Dutta, S ^a   Ghosh, A ^a   Mukherjee, J ^a,c   Acharya, S ^a   Goswami, S ^a   Mazumdar, A ^a   Chaudhuri, S ^b   Chaudhuri, Swapna ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Astrocytoma; Chemotherapy; Immune status; Meningioma; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; E ROSETTE; GLIOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE STATUS; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOTOXICITY; MACROPHAGE; MENINGIOMA; METASTASIS; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTIGENS, CD2; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; GLIOMA; HUMANS; IMMUNE TOLERANCE; MACROPHAGES; MENINGIOMA; NEOPLASM INVASIVENESS; PHAGOCYTOSIS; RADIOTHERAPY; ROSETTE FORMATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33750080502     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600814839     Document Type: Article

References (44)

1. Dix, A.R.; Brooks, W.H.; Roszman, T.L.; Morford, L.A.; Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol; 1999, 100, 216-232.
2. Bodmer, S.; Strommer, K.; Frei, K.; Siepl, C.; de Tribolet, N.; Heid, I.; et al. Immunosuppression and transforming growth factor-beta in glioblastoma. referential production of transforming growth factor-beta 2. J. Immunol. 1989, 43, 3222-3229.
3. Bodmer, S.; Huber, D.; Heid, I.; Fontana, A. Human glioblastoma cell derived transforming growth factor-beta 2: Evidence for secretion of both high and low molecular weight biologically active forms. J Neuroimmunol. 1991, 34, 33-42.
4. De Martin, R.; Haendler, B.; Hofer-Warbinek, R.; Gaugitsch, H.; Wrann Schlusener, H.; Seifert, J.M.; et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 1987, 6, 3673-3677.
5. Fontana, A.; Hengartner, H.; de Tribolet, N.; Weber, E. Glioblastoma cells release Interleukin 1 and factors inhibiting interleukin2-mediated effects. J Immunol. 1984, 132, 1837-1844.
6. Kuppner, M.C.; Hamou, M.F.; Sawamura, Y.; Bodmer, S.; de Tribolet, N.; Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J. Neurosurg. 1989, 71, 211-217.
7. Siepl, C.; Bodmer, S.; Frei, K.; MacDonald, H.R.; De Martin, R.; Hofer, E.; et al. The glioblastoma-derived, T cell suppressor factor transforming growth factor-beta 2 inhibits, T.; cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J. Immunol. 1988, 18, 593-600.
8. Wrann, M.; Bodmer, S.; de Martin, R.; Siepl, C.; Hofer-Warbinek, R.; Frei, K.; et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 1987, 6, 1633-1636.
9. Castelli, M.G.; Chiabrando, C.; Fanelli, R.; Martelli, L.; Butti, G.; Gaetani, P.; et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res. 1989, 49, 1505-1508.
10. Couldwell, W.T.; DoreDuffy, P.; Apuzzo, M.L.; Antel, J.P. Malignant glioma modulation of immune function: Relative contribution of different soluble factors. J Neuroimmunol. 1991, 33, 89-96.
11. Bogdan, C.; Nathan, C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. NY Acad. Sci. 1993, 685, 713-739.
12. Ding, L.; Shevach, E.M. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol. 1992, 148, 3133-3139.
13. Fiorentino, D.F.; Zlotnik, A.; Vieira, P.; Mosmann, T.R.; Howard, M.; Moore, K.W. et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991, 46, 3444-3451.
14. Taga, K.; Tosato, G. IL-10 inhibit human T cell proliferation and IL-2 production. J. Immunol. 1992, 148, 1143-1148.
15. Merritt, W.D.; Bailey, J.M.; Pluznik, D.H.; Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol. 1984, 89, 1-10.
16. Offner, H.; Thieme, T.; Vandenbark, A.A. Gangliosides induce selective modulation of CD4 from helper, T.; lymphocytes, J. Immunol. 1987, 139, 3295-3305.
17. Nidus Information Services, Inc., 41 East 11th Street, 11th Floor, New York, NY 10003 or email office@well-connected.com or on the internet at www.well-connected.com.
18. DeAngelis, L.M. Brain Tumors. The New England J. of Med. 2001, 344, (2): 114-123.
19. Stahnke, K.; Simone, F.; Friesen, C.; Straub, G.; Debatin, K.M.; Activation of apoptosis pathways in peripheral blood lymphocytes in in vivo chemotherapy. Neoplasia. 2001, 98 (10), 3066-3073.
20. Louagie, H.; Van Eijkeren, M.; Philippe, L.; Thierens, H.; Ridder de, L. Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int. J. of Radiation. Biol. 1999, 75, (6), 767-771.
21. Willams, J.L.; Patchen, M.L.; Darden, J.H.; Jackson, W.E.; Effects of radiation on survival and recovery of T lymphocyte subsetw in C3H/HeN mice. Exp. Hematol. 1994, 22 (6), 510-516.
22. Schedule Y (amended version, 2005), Indian Drug and Cosmetic Law, 1940. Website: www.cdsco.nic.in
23. Good clinical Practice, Central Drugs standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India, New Delhi. Drug Controller General, India.
24. Mukherjee, J.; Sarkar, S.; Ghosh, A.; Duttagupta, A.K.; Chaudhuri, S.; Chaudhuri Swapna. Immunotherapeutic effects of T11TS/SLFA-3 against nitrosocompound mediated neural genotoxicity. Tox. Lett. 2004, 150, (3): 239-257.
25. Mukherjee, J.; Sarkar, S.; Begurn, Z.; Dutta, S.; Ghosh, A.; Chaudhuri, S.; Chaudhuri, Swapna. Preclinical changes in immunoreactivity and cellular architecture during the progressive development of intracranial neoplasm and its immunotherapeutic schedule with a novel biological response modifier, the T11TS/SLFA-3. Asian Pacific J. Cancer Prevention. 2002, 3, 325-337.
26. Sarkar, S.; Begum, Z.; Dutta, S.; Chaudhuri, S.; Chaudhuri Swapna. Sheep form of Leucocyte Function Antigen-3 (T IITS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor: A new approach to biological response modifier therapy. J. Exp. Clin. Cancer Res. 2002, 21(1), 95-106.
27. Mackall, C.-L.; Fleisher, T.-A.; Brown, M.-R.; et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994, 84, 2221-2228.
28. Mackall, C.-L., Hakim, F.-T., Gress, R.-E. Restoration of T cell homeostasis after T cell depletion. Semin Immunol. 1997, 9, 339-346.
29. Brooks, W.H.; Netsky, M.G.; Normansell, D.E.; Horwitz, D.A. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 1972, 136, 1631-1647.
30. Mahaley, M.S. Jr.; Brooks, W.H.; Roszman, T.L.; Bigner, D.D.; Dudka, L. Ialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas. J. Neurochem. 1988, 50, 912-919.
31. Young, H.F.; Kaplan, A.M. Cellular immune deficiency in patients with glioblastoma. Surg. Forum. 1976, 27, 476-478.
32. Brooks, W.H.; Roszman, T.L.; Mahaley, M.S.; Woosley, R.E. Immunobiology of primary intracranial tumours: II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin. Exp. Immunol. 1977, 29, 61-66.
33. Mizoguchi, H.; O'Shea, J.J.; Longo, D.L.; Loeffler, C.M.; McVicar, D.W.; Ochoa, A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258, 1795-1798.
34. Gratas, C.; Tohma, Y.; Van Meir, E.G.; Klein, M.; Tenan, M.; Ishii, N.; Tachibana, O.; Kleihues, P.; Ohgaki, H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997, 7, 863-869.
35. Saas, P.; Walker, P.R.; Hahne, M.; Quiquerez, A.L.; Schnuriger, V.; Perrin, G. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 1997, 99, 1173-1178.
36. Weller, M.; Weinstock, C.; Will, C.; Wagenknecht, B.; Dichgans, J.; Lang, F.; Gulbins, E. CD95-dependent, T cell killing by glioma Cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol. Biochem. 1997, 7, 282-288.
37. Weller, M.; Kleihus, P.; Dichgans, J.; Ohgaki, H. CD95 ligand: Lethal weapon against malignant glioma. Brain Pathology. 1998, 8, 285-293.
38. Hong, J.H.; Chiang, C.S.; Campbell, I.L.; Sun, J.R.; Withers, H.R.; McBride, W.H. Induction of acute phase gene expression by brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33, 619-626.
39. Plevova, P. Radiotherapy and chemotherapy-induced normal tissue damage: the role of cytokines and adhesion molecules. Radiol. Oncol. 2002 36 (2), 109-119.
40. Schwaighofer, H.; Kernan, N.A.; O'Reilly, R.J.; Brankova, J.; Nachbaur, D.; Herold, M.; et al. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. Transplantation. 1996, 62, 947-953.
41. Sigurdson, J.A.; Jones, I.M. Second cancers after radiotherapy: any evidence for radiation induced genomic instability. Oncogene. 2003, 22, 7018-7027.
42. Pardoll, D.T. cells and tumors. Nature 411, 1010-1012.
43. Plunkett, M.L.; Sanders, M.E.; Selvaraj, P.; et al. Rosetting of activated human, T.; lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function associated antigen 3 (LFA-3). J. Exp. Med. 1987, 165, 664-676.
44. Raha, S.K.; Dey, S.K.; Roy, S.K. Antitumor activity of Lasparaginase from Cylindrocarpon obstutisporum MB10 and its effect on the immune system. Biochem. Int. 1990 21, 987-1000.